A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer

References

1. Female breast cancer — cancer stat facts.
   (Available at:)
   https://seer.cancer.gov/statfacts/html/breast.html
   (Accessed January 2, 2021)
   View in Article

   • Google Scholar
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer. NCCN.org.
   (Available at:)
   https://www.nccn.org/guidelines/category_1

   Date: 2021
   (Accessed April 26, 2021)
   View in Article

   • Google Scholar
3. • Jørgensen J.T.
   • Hersom M.
   Companion diagnostics-a tool to improve pharmacotherapy.
   Ann Transl Med. 2016; 4https://doi.org/10.21037/atm.2016.12.26
   View in Article

   • Google Scholar
4. • U.S. FDA
   Developing and labeling in vitro companion diagnostic devices for a specific group of oncology therapeutic products guidance for industry. FDA guidance documents.
   (Available at:)
   https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances

   Date: 2020
   (Accessed April 25, 2021)
   View in Article

   • Google Scholar
5. • U.S. FDA
   List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools).
   (Available at:)
   https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

   Date: 2021
   (Accessed April 28, 2021)
   View in Article

   • Google Scholar
6. • Allott E.H.
   • Geradts J.
   • Sun X.
   • et al.
   Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
   Breast Cancer Res. 2016; 18: 1-11
   View in Article

   • Google Scholar
7. • Jabbour M.N.
   • Massad C.Y.
   • Boulos F.I.
   Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma.
   Breast Cancer Res Treat. 2012; 135: 29-37
   View in Article

   • Google Scholar
8. • Amir E.
   • Clemons M.
   • Purdie C.A.
   • et al.
   Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
   Cancer Treat Rev. 2012; 38: 708-714
   View in Article

   • Google Scholar
9. • Bardou V.J.
   • Arpino G.
   • Elledge R.M.
   • et al.
   Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
   J Clin Oncol. 2003; 21: 1973-1979
   View in Article

   • Google Scholar
10. • Van Poznak C.
    • Somerfield M.R.
    • Bast R.C.
    • et al.
    Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline.
    J Clin Oncol. 2015; 33: 2695-2704
    View in Article

    • Google Scholar
11. • Hoefnagel L.D.C.
    • Moelans C.B.
    • Meijer S.L.
    • et al.
    Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases.
    Cancer. 2012; 118: 4929-4935
    View in Article

    • Google Scholar
12. • Allison K.H.
    • Hammond M.E.H.
    • Dowsett M.
    • et al.
    Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.
    J Clin Oncol. 2020; 38: 1346-1366
    View in Article

    • Google Scholar
13. • Wolff A.C.
    • Elizabeth Hale Hammond M.
    • Allison K.H.
    • et al.
    Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update.
    J Clin Oncol. 2018; 36: 2105-2122
    View in Article

    • Google Scholar
14. Estrogen and progesterone receptor testing in breast cancer guideline update. American Society of Clinical Oncology/College of American Pathologists, 2020 (Available at:)
    https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/guideline-recommendations-for-immunohistochemical-testing-of-estrogen-and-progesterone-receptors-in-breast-cancer
    (Accessed April 19, 2021)
    View in Article

    • Google Scholar
15. HER2 testing in breast cancer. American Society of Clinical Oncology/College of American Pathologists, 2018 (Available at:)
    https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer
    (Accessed April 26, 2021)
    View in Article

    • Google Scholar
16. • Chen M.T.
    • Sun H.F.
    • Zhao Y.
    • et al.
    Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis.
    Sci Rep. 2017; 7: 1-8
    View in Article

    • Google Scholar
17. • Clark B.Z.
    • Yoest J.M.
    • Onisko A.
    • et al.
    Effects of hydrochloric acid and formic acid decalcification on breast tumor biomarkers and HER2 fluorescence in situ hybridization.
    Appl Immunohistochem Mol Morphol. 2019; 27: 223-230
    View in Article

    • Google Scholar
18. • van Es S.C.
    • van der Vegt B.
    • Bensch F.
    • et al.
    Decalcification of breast cancer bone metastases With EDTA does not affect ER, PR, and HER2 results.
    Am J Surg Pathol. 2019; 43: 1355-1360
    View in Article

    • Google Scholar
19. • Pareja F.
    • Murray M.P.
    • Jean R.D.
    • et al.
    Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.
    J Am Soc Cytopathol. 2017; 6: 33-40
    View in Article

    • Google Scholar
20. • Cimino-Mathews A.
    Tumor-in filtrating lymphocytes and PD-L1 in breast cancer (and, what happened to medullary carcinoma?).
    Diagn Histopathol. 2021; : 1-7
    View in Article

    • Google Scholar
21. • Cortes J.
    • Cescon D.W.
    • Rugo H.S.
    • et al.
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020; 396: 1817-1828
    View in Article

    • Google Scholar
22. • Schmid P.
    • Adams S.
    • Rugo H.S.
    • et al.
    Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer.
    N Engl J Med. 2018; 379: 2108-2121
    View in Article

    • Google Scholar
23. • Schmid P.
    • Cortes J.
    • Pusztai L.
    • et al.
    Pembrolizumab for early triple-negative breast cancer.
    N Engl J Med. 2020; 382: 810-821
    View in Article

    • Google Scholar
24. • Cimino-Mathews A.
    • Ye X.
    • Meeker A.
    • et al.
    Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Hum Pathol. 2013; 44: 2055-2063
    View in Article

    • Google Scholar
25. • Michot J.M.
    • Bigenwald C.
    • Champiat S.
    • et al.
    Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Eur J Cancer. 2016; 54: 139-148
    View in Article

    • Google Scholar
26. • Fusco M.J.
    • West H.J.
    • Walko C.M.
    Tumor mutation burden and cancer treatment.
    JAMA Oncol. 2021; 7: 316
    View in Article

    • Google Scholar
27. • Cheng A.S.
    • Leung S.C.Y.
    • Gao D.
    • et al.
    Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020; 179: 3-10
    View in Article

    • Google Scholar
28. • Barroso-Sousa R.
    • Jain E.
    • Cohen O.
    • et al.
    Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Ann Oncol. 2020; 31: 387-394
    View in Article

    • Google Scholar
29. • Marabelle A.
    • Fakih M.
    • Lopez J.
    • et al.
    Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
    Lancet Oncol. 2020; 21: 1353-1365
    View in Article

    • Google Scholar
30. • U.S. FDA
    FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer. Drug approvals and databases.
    (Available at:)
    https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer
    (Accessed April 26, 2021)
    View in Article

    • Google Scholar
31. • Venetis K.
    • Sajjadi E.
    • Haricharan S.
    • et al.
    Mismatch repair testing in breast cancer: The path to tumor-specific immuno-oncology biomarkers.
    Transl Cancer Res. 2020; 9: 4060-4064
    View in Article

    • Google Scholar
32. • Fusco N.
    • Lopez G.
    • Corti C.
    • et al.
    Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability.
    JNCI Cancer Spectr. 2018; 2https://doi.org/10.1093/jncics/pky056
    View in Article

    • Google Scholar
33. • Winter C.
    • Nilsson M.P.
    • Olsson E.
    • et al.
    Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
    Ann Oncol. 2016; 27: 1532-1538
    View in Article

    • Google Scholar
34. • Nik-Zainal S.
    • Davies H.
    • Staaf J.
    • et al.
    Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
    Nature. 2016; 534: 47-54
    View in Article

    • Google Scholar
35. • Sønderstrup I.M.H.
    • Jensen M.B.R.
    • Ejlertsen B.
    • et al.
    Subtypes in BRCA-mutated breast cancer.
    Hum Pathol. 2019; 84: 192-201
    View in Article

    • Google Scholar
36. • Robson M.
    • Im S.-A.
    • Senkus E.
    • et al.
    Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation.
    N Engl J Med. 2017; 377: 523-533
    View in Article

    • Google Scholar
37. • Tung N.M.
    • Robson M.E.
    • Ventz S.
    • et al.
    TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes.
    J Clin Oncol. 2020; 38: 4274-4282
    View in Article

    • Google Scholar
38. • André F.
    • Ciruelos E.
    • Rubovszky G.
    • et al.
    Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer.
    N Engl J Med. 2019; 380: 1929-1940
    View in Article

    • Google Scholar
39. • Martínez-Saéz O.
    • Chic N.
    • Pascual T.
    • et al.
    Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Breast Cancer Res. 2020; 22: 1-9
    View in Article

    • Google Scholar
40. • U.S. FDA
    FDA approves first PI3K inhibitor for breast cancer.
    (Available at:)
    https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer
    (Accessed April 26, 2021)
    View in Article

    • Google Scholar
41. • U.S. FDA
    FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers.
    (Available at:)
    https://www.fda.gov/drugs/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers
    (Accessed April 26, 2021)
    View in Article

    • Google Scholar
42. • U.S. FDA
    FDA approves alpelisib for metastatic breast cancer.
    (Available at:)
    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer
    (Accessed April 26, 2021)
    View in Article

    • Google Scholar
43. • Scott L.J.
    Larotrectinib: first global approval.
    Drugs. 2019; 79: 201-206
    View in Article

    • Google Scholar
44. • Al-Salama Z.T.
    • Keam S.J.
    Entrectinib: first global approval.
    Drugs. 2019; 79: 1477-1483
    View in Article

    • Google Scholar
45. • Diallo R.
    • Schaefer K.L.
    • Bankfalvi A.
    • et al.
    Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry.
    Hum Pathol. 2003; 34: 1299-1305
    View in Article

    • Google Scholar
46. • Harrison B.T.
    • Fowler E.
    • Krings G.
    • et al.
    Pan-TRK immunohistochemistry.
    Am J Surg Pathol. 2019; 43: 1693-1700
    View in Article

    • Google Scholar
47. • U.S. FDA
    FDA approves companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi.
    (Available at:)
    https://www.fda.gov/drugs/fda-approves-companion-diagnostic-identify-ntrk-fusions-solid-tumors-vitrakvi
    (Accessed April 25, 2021)
    View in Article

    • Google Scholar
48. • Remoué A.
    • Conan-Charlet V.
    • Bourhis A.
    • et al.
    Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expression.
    Pathol Int. 2019; 69: 94-96
    View in Article

    • Google Scholar
49. • Canzoniero J.V.L.
    • Park B.H.
    Use of cell free DNA in breast oncology.
    Biochim Biophys Acta. 2016; 1865: 266-274
    View in Article

    • Google Scholar
50. • Buono G.
    • Gerratana L.
    • Bulfoni M.
    • et al.
    Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?.
    Cancer Treat Rev. 2019; 73: 73-83
    View in Article

    • Google Scholar
51. • Tan P.H.
    • Ellis I.
    • Allison K.
    • et al.
    The 2019 World Health Organization classification of tumours of the breast.
    Histopathology. 2020; 77: 181-185
    View in Article

    • Google Scholar
52. • Tan P.H.
    • Ellis I.
    • Allison K.
    • et al.
    World Health Organization Classification of Tumours: breast tumors.
    5th edition. Vol 2. IARC Press, Lyon, France2019
    View in Article

    • Google Scholar
53. • Dermawan J.K.
    • Mukhopadhyay S.
    • Shah A.A.
    Frequency and extent of cytokeratin expression in paraganglioma: an immunohistochemical study of 60 cases from 5 anatomic sites and review of the literature.
    Hum Pathol. 2019; 93: 16-22
    View in Article

    • Google Scholar
54. • Tarantino P.
    • Hamilton E.
    • Tolaney S.M.
    • et al.
    HER2-low breast cancer: pathological and clinical landscape.
    J Clin Oncol. 2020; 38: 1951-1962
    View in Article

    • Google Scholar